SiriusXM XM Holdings Inc (NASDAQ:SIRI) announced that it will air a special broadcast of “El Show de Piolin” on Saturday, March 8 during the upcoming blockbuster Pay-Per-View boxing event, “TOE TO TOE: Canelo vs. Angulo,” featuring Mexican boxing superstar “Canelo” Alvarez facing veteran fellow countryman Alfredo “El Perro” Angulo. Sirius XM Holdings Inc (NASDAQ:SIRI) stock performance was 0.14% in last session and finished the day at $3.56. Traded volume was 46,431,856 million shares in the last session and the average volume of the stock remained 66.42 million shares. The beta of the stock remained 2.03. Sirius XM Holdings Inc (NASDAQ:SIRI) insider ownership is 53.10%.

Zynga Inc (NASDAQ:ZNGA) stock shot up at the end of January 2014 after the company released its fourth quarter results. It appears that it wasn’t an impulse buy from investors as the uptrend continued throughout the next month. And now, the company’s shares saw another moderate jump following management’s statements at a recent Morgan Stanley conference. Zynga Inc (NASDAQ:ZNGA) dropped -3.16 percent to $5.51 yesterday on volume of 26.24million shares. The intra-day range of the stock was $5.46 to $5.70. Zynga Inc (NASDAQ:ZNGA) has a market capitalization of $4.49 million.

Micron Technology, Inc. (NASDAQ:MU) this week announced that Darren Thomas has been named as vice president of Micron’s Storage business unit. Micron Technology, Inc. (NASDAQ:MU)’s stock on Mar 6, 2014 reported a decrease of -0.24% to the closing price of $24.77. Its fifty two weeks range is $8.64-$25.68. The total market capitalization recorded $26.28billion. The overall volume in the last trading session was 32,308,968 million shares. In its share capital, Micron Technology, Inc. (NASDAQ:MU) has 1.05 million outstanding shares.

Peregrine Pharmaceuticals (NASDAQ:PPHM) on Mar. 4 announced the presentation of data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies at two upcoming Keystone Symposia to be held March 9-13, 2014. Bavituximab, the company’s lead immunotherapy candidate, is advancing in a Phase III SUNRISE trial for the treatment of second-line non-small cell lung cancer. On Thursday, shares of Peregrine Pharmaceuticals (NASDAQ:PPHM) dropped -7.45% to close the day at $2.61. Company return on investment (ROI) is -126.10% and its monthly performance is recorded as 49.14%. Peregrine Pharmaceuticals (NASDAQ:PPHM) quarterly revenue growth is 94.78%.